The estimated Net Worth of Kristin C Peck is at least $46.4 millió dollars as of 20 February 2024. Ms. Peck owns over 13,000 units of Zoetis Inc stock worth over $17,548,616 and over the last 12 years she sold ZTS stock worth over $25,559,608. In addition, she makes $3,330,160 as Chief Executive Officer és Director at Zoetis Inc.
Kristin has made over 31 trades of the Zoetis Inc stock since 2016, according to the Form 4 filled with the SEC. Most recently she exercised 13,000 units of ZTS stock worth $599,170 on 20 February 2024.
The largest trade she's ever made was exercising 36,813 units of Zoetis Inc stock on 10 February 2024 worth over $6,994,102. On average, Kristin trades about 3,068 units every 19 days since 2012. As of 20 February 2024 she still owns at least 92,366 units of Zoetis Inc stock.
You can see the complete history of Ms. Peck stock trades at the bottom of the page.
Kristin C. Peck serves as Chief Executive Officer, Director of the Company. Prior to becoming CEO, Ms. Peck was executive vice president and group president, U.S. Operations, Business Development and Strategy at Zoetis from March 2018 to December 2019. Ms. Peck previously served as our Executive Vice President and President, U.S. Operations from May 2015 to February 2018 and Executive Vice President and Group President from October 2012 through April 2015. In these roles, Ms. Peck helped usher Zoetis through its Initial Public Offering in 2013 and has been a driving force of change in areas including Global Manufacturing and Supply, Global Poultry, Global Diagnostics, Corporate Development, and New Product Marketing and Global Market Research. Before joining Zoetis, Ms. Peck served as Executive Vice President, Worldwide Business Development and Innovation at Pfizer Inc. and as a member of Pfizer’s Executive Leadership Team. Prior to joining Pfizer, Ms. Peck held roles at The Boston Consulting Group (BCG) as well as in private equity and real estate finance at The Prudential Realty Group, The O’Connor Group and J.P. Morgan. Ms. Peck has been a member of the Thomson Reuters’ Board of Directors since September 2016 and is also a member of the Advisory Board for the Deming Center for Quality, Productivity and Competitiveness at Columbia Business School. As a recipient of the 2019 Feather in Her Cap Award, she has been recognized for her leadership and contributions to the animal health industry, and her work in mentoring women and helping them advance their careers in animal health. Ms. Peck holds a bachelor’s degree from Georgetown University and an MBA from Columbia Business School. Ms. Peck’s knowledge and leadership of our company as its current CEO, her animal health and pharmaceutical industry experience, along with her public company board experience, make her a valuable member of our Board.
As the Chief Executive Officer és Director of Zoetis Inc, the total compensation of Kristin Peck at Zoetis Inc is $3,330,160. There are 1 executives at Zoetis Inc getting paid more, with Glenn David having the highest compensation of $3,672,350.
Kristin Peck is 48, she's been the Chief Executive Officer és Director of Zoetis Inc since 2020. There are 21 older and 1 younger executives at Zoetis Inc. The oldest executive at Zoetis Inc is William Steere, 83, who is the Independent Director.
Over the last 12 years, insiders at Zoetis Inc have traded over $876,669,659 worth of Zoetis Inc stock and bought 1,602,140 units worth $77,083,975 . The most active insiders traders include Square Capital Management, ..., Frank A Damelio és Michael B Mccallister. On average, Zoetis Inc executives and independent directors trade stock every 14 days with the average trade being worth of $14,414,921. The most recent stock trade was executed by Soria Ester Banque on 31 July 2024, trading 895 units of ZTS stock currently worth $170,041.
Zoetis Inc. is an American drug company, the worlds largest producer of medicine and vaccinations for pets and livestock. The company was a subsidiary of Pfizer, the worlds largest drug maker, but with Pfizers spinoff of its 83% interest in the firm it is now a completely independent company.
Zoetis Inc executives and other stock owners filed with the SEC include: